Yingying Huang

Yingying Huang

Auto-generated profile, based on publicly available information

Yingying Huang

Center for Tumor Diagnosis & Therapy Jinshan Hospital Fudan University Shanghai China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
KRAS mutations are causally linked to protumor inflammation and are identified as driving factors in tumorigenesis. Here, using multiomics data gathered from a large set of patients, we showed that KRAS mutation was associated with a specific landscape of alternative mRNA splicing that connected to myeloid inflammation in intrahepatic cholangiocarcinoma (iCCA). Then, we identified a negative feedback mechanism in which the upregulation of interleukin 1 receptor antagonist (IL1RN)-201/203 due to alternative splicing confers vital anti-inflammatory effects in KRAS-mutant iCCA. In KRAS-mutant iCCA mice, both IL1RN-201/203 upregulation and anakinra treatment ignited a significant antitumor immune response by altering neutrophil recruitment and phenotypes. Furthermore, anakinra treatment synergistically enhanced anti–PD-1 therapy to activate intratumoral GZMB+ CD8+ T cells in KRAS-mutant iCCA mice. Clinically, we found that high IL1RN-201/203 levels in patients with KRAS-mutant iCCA were significantly associated with superior response to anti–PD-1 immunotherapy. Significance: This work describes a novel inflammatory checkpoint mediated by IL1RN alternative splicing variants that may serve as a promising basis to develop therapeutic options for KRAS-mutant iCCA and other cancers. This article is featured in Selected Articles from This Issue, p. 2109

16 September 2024
Verified
Other
Open access
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
Supplementary Table S6. GO term and KEGG pathway information in Gzmb+ Cd8+ T cells.

2 October 2026 in Advanced Materials
Verified
Journal Article
Closed access
WWWenbo Wang
Wenbo Wang
BRBiyu Rui
Biyu Rui
GWGuixia Wang
Guixia Wang
ZRZesong Ruan
Zesong Ruan
ZLZhiyuan Luo
Zhiyuan Luo
YCYunfeng Chen
Yunfeng Chen

12 December 2025
Verified
Other
Open access
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
Supplementary Figure S1. Determination of AS index in iCCA. Supplementary Figure S2. Validation of distinct immune features in iCCA. Supplementary Figure S3. Detection of KRAS mutation associated indicators. Supplementary Figure S4. Exploration of the molecular mechanisms of IL1RN201/203 in iCCA. Supplementary Figure S5. Comparison between KRAS mutant (YAK) or KRASWT (YA) iCCA mice and functional validation of IL1RN-201/203. Supplementary Figure S6. Definition, validation and functional exploration of neutrophil clusters. Supplementary Figure S7. Effects of T cells, especially GZMB+ CD8+ T cells, on IL1RN-201/203 efficacy. Supplementary Figure S8. The roles of anti-PD1 Ab in KRASWT iCCA mice and anti-PD1 Ab plus anakinra in KRAS mutant iCCA mice. Supplementary Figure S9. Immunologic features of cancer patients with or without KRAS mutation.

16 September 2024
Verified
Other
Open access
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
Supplementary Table S1. Samples and transcriptomics information.

16 September 2024
Verified
Other
Open access
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
Supplementary Table S4. Neutrophil-related information.